Cargando…
PAK1 and Therapy Resistance in Melanoma
Malignant melanoma claims more lives than any other skin malignancy. While primary melanomas are usually cured via surgical excision, the metastatic form of the disease portents a poor prognosis. Decades of intense research has yielded an extensive armamentarium of anti-melanoma therapies, ranging f...
Autores principales: | Kichina, Julia V., Maslov, Alexei, Kandel, Eugene S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572217/ https://www.ncbi.nlm.nih.gov/pubmed/37830586 http://dx.doi.org/10.3390/cells12192373 |
Ejemplares similares
-
The response to PAK1 inhibitor IPA3 distinguishes between cancer cells with mutations in BRAF and Ras oncogenes
por: Singhal, Ruchi, et al.
Publicado: (2012) -
Proteotoxic Stress as an Exploitable Vulnerability in Cells with Hyperactive AKT
por: Babagana, Mahamat, et al.
Publicado: (2021) -
Differential roles and regulation of the protein kinases PAK4, PAK5 and PAK6 in melanoma cells
por: Murugesan, Gavuthami, et al.
Publicado: (2022) -
MicroRNA analysis suggests an additional level of feedback regulation in the NF-κB signaling cascade
por: Mechtler, Peter, et al.
Publicado: (2015) -
PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions
por: Grebeňová, Dana, et al.
Publicado: (2019)